JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Sterling Auty maintains an Overweight rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $8 to $10.
August 09, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Cellebrite DI and raises the price target from $8 to $10, indicating a positive outlook for the stock.
The raised price target by JP Morgan indicates a positive outlook for Cellebrite DI. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100